Thrombosis in myeloma treated with IMiDs.
Survival of myeloma patients has improved since the introduction of novel agents in the armamentorium, especially with the Immunomodulator drugs (IMiDs). However, this substantial benefit has been counterbalanced by the dramatic increase of the incidence rate of thromboembolic events, either venous and/or arterial. This observation has made compulsory a prophylactic treatment in myeloma treated with IMiDs. Although guidelines were proposed since, it is clear that several unanswered questions remain, starting with the choice of the thromboprophylaxis and the definition of risk factors. Further studies are warranted to help decide the optimal thromboprophylaxis.